Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.

[1]  M. Shaw,et al.  A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters , 2023, Frontiers in Plant Science.

[2]  M. O’Kennedy,et al.  Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits , 2023, Vaccine.

[3]  W. Phoolcharoen,et al.  Chapter 12 SARS-CoV-2 vaccines: current trends and prospects of developing plant-derived vaccines , 2022, Biomedical Innovations to Combat COVID-19.

[4]  X. Fang,et al.  A potent, broadly protective vaccine against SARS-CoV-2 variants of concern , 2022, npj Vaccines.

[5]  D. Vinh,et al.  Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19 , 2022, Nature Communications.

[6]  Jie Zhou,et al.  Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines , 2022, Journal of medical virology.

[7]  J. Izopet,et al.  Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection , 2022, Vaccines.

[8]  A. West,et al.  Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models , 2022, Science.

[9]  N. Heaton,et al.  The Impact of Estrogens and Their Receptors on Immunity and Inflammation during Infection , 2022, Cancers.

[10]  I. Mysorekar,et al.  Golden Syrian Hamsters as a Model for Revisiting the Role of Biological Sex Differences in SARS-CoV-2 Infection , 2021, mBio.

[11]  S. Madhi,et al.  Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. , 2021, Vaccine.

[12]  Priya S. Shah,et al.  Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases , 2021, Plant biotechnology journal.

[13]  Marc‐André D'Aoust,et al.  Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19 , 2021, Nature Medicine.

[14]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[15]  M. Giordano,et al.  Immune system and COVID-19 by sex differences and age , 2021, Women's health.

[16]  T. Vesikari,et al.  Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials , 2020, The Lancet.

[17]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[18]  G. Lomonossoff,et al.  pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. , 2009, Plant biotechnology journal.

[19]  R. Roden,et al.  Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines , 2009, Journal of Virology.

[20]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.